-K Yamanishi Researcher Activity Profile

Research Author Detailed Information 

K Yamanishi Publication Rate By Year

K Yamanishi has published 1 paper(s) in 1991, 1 paper(s) in 1993, 2 paper(s) in 1994, 10 paper(s) in 2007, 5 paper(s) in 2008, for a total of 19 research publications in total.

K K Yamanishi Author Information

LAST NAME: yamanishi

FIRST NAME: K

INITIALS: k

AFFILIATION:

Papers

K Yamanishi's Publication Record

1. Positive and negative regulation of adenovirus infection by CAR-like soluble protein, CLSP. Year Published: 2007
Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, Osaka, Japan.
2. A simple and effective technique for the cryotherapy of digital mucous cysts. Year Published: 2007
Department of Dermatology, Hyogo College of Medicine, Hyogo, Japan. show@hyo-med.ac.jp
3. Deletion in open reading frame 49 of varicella-zoster virus reduces virus growth in human malignant melanoma cells but not in human embryonic fibroblasts. Year Published: 2007
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8, Saito-Asagi, Ibaraki, Osaka, Japan.
4. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Year Published: 2007
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
5. Renaturation, purification, and characterization of human truncated macrophage colony-stimulating factor expressed in Escherichia coli. Year Published: 1991
Cellular Technology Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima.
6. Structural analysis of recombinant human carboxy-terminal-truncated macrophage colony-stimulating factor. Year Published: 1993
Cellular Technology Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima.
7. The structure of recombinant human carboxy-terminal-truncated macrophage colony-stimulating factor derived from mammalian cells. Year Published: 1994
Cellular Technology Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima.
8. Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine. Year Published: 2007
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
9. Deletion in open reading frame 49 of varicella-zoster virus reduces virus growth in human malignant melanoma cells but not in human embryonic fibroblasts. Year Published: 2007
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8, Saito-Asagi, Ibaraki, Osaka, Japan.
10. Varicella-zoster virus glycoprotein M homolog is glycosylated, is expressed on the viral envelope, and functions in virus cell-to-cell spread. Year Published: 2008
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8, Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
11. Positive and negative regulation of adenovirus infection by CAR-like soluble protein, CLSP. Year Published: 2007
Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, Osaka, Japan.
12. Single dose of inactivated Japanese encephalitis vaccine with poly(gamma-glutamic acid) nanoparticles provides effective protection from Japanese encephalitis virus. Year Published: 2008
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
13. Varicella-zoster virus glycoprotein M homolog is glycosylated, is expressed on the viral envelope, and functions in virus cell-to-cell spread. Year Published: 2008
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8, Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
14. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Year Published: 2007
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
15. Detection of human alpha-herpesvirus DNA using consensus primers and specific probes. Year Published: 1994
Department of Virology, Osaka University, Japan.
16. Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine. Year Published: 2007
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
17. Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine. Year Published: 2007
Laboratory of Virology and Vaccinology, Division of Biomedical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
18. In silico study of whey-acidic-protein domain containing oral protease inhibitors. Year Published: 2008
Hirakata Ryoikuen, Tsudahigashi 2-1-1, Hirakata, Osaka 573-0122, Japan.
19. Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. Year Published: 2008
Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan. kyamanis@hyo-med.ac.jp.